Equities researchers at Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 94.17% from the company’s current price.
Separately, Guggenheim assumed coverage on shares of Sionna Therapeutics in a report on Tuesday. They set a “buy” rating and a $45.00 price objective on the stock.
View Our Latest Research Report on SION
Sionna Therapeutics Price Performance
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Stock Splits, Do They Really Impact Investors?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
